Literature DB >> 12135846

Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection.

Niels Frimodt-Møller1.   

Abstract

Antibiotic treatment of urinary tract infection (UTI) depends on the antibiotic being able to inhibit the growth or to kill the bacteria present in the urinary tract. The pharmacokinetics of antibiotics in the urinary tract including the kidneys, the bladder and the prostate are briefly reviewed. The conclusion is that high urinary antibiotic concentrations can eradicate bacteria in the urine, but in the kidney tissue levels must surpass the MIC of the infecting pathogen to achieve effect. Pharmacodynamic studies in UTI are relatively scarce, but recent studies have shown, that as for other types of infections, beta-lactam antibiotic treatment of UTI depends on the T(>MIC), i.e. the time the antibiotic concentration remains above the MIC. This counts for activity against bacteria in the kidneys as well as in the urine. Bacterial counts in the bladder are curiously resistant to the activity of most antibiotics. For drugs with concentration dependent time-kill activity such as the fluoroquinolones and the aminoglycosides, the effect in UTIs is dependent on the peak/MIC ratio or AUC/MIC ratio. The aminoglycosides are difficult to evaluate in this context, since they are bound in high concentrations to the renal cortex. For clinical studies the author reviews the literature for aminopenicillins (ampicillin and amoxycillin) as representatives of beta-lactam antibiotics. Data from 16 studies of uncomplicated UTI encompassing 20 treatment groups showed a significant correlation between the cumulative T(>MIC) and bacteriological cure, such that a cumulative T(>MIC) of 30 h was necessary for a maximal cure rate of 80-90%. Incorporating these data including the T(>MIC) for the aminopenicillins, the optimal dose with minimal consumption of drug can be calculated, i.e. for amoxycillin 500 mg TID for 4 days. Further research is needed to calculate optimal dosages for other types of antibiotics, especially in order to prevent development of resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135846     DOI: 10.1016/s0924-8579(02)00105-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  29 in total

1.  Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections.

Authors:  Keith Miller; Alexander John O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-09       Impact factor: 3.267

Review 3.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 4.  The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.

Authors:  Y-H Chen; W-C Ko; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-04       Impact factor: 3.267

Review 5.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes.

Authors:  Jennifer A Jolley; Deborah A Wing
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

7.  Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.

Authors:  Nayara Helisandra Fedrigo; Josmar Mazucheli; James Albiero; Danielle Rosani Shinohara; Fernanda Gomes Lodi; Ana Cristina Dos Santos Machado; Sherwin K B Sy; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children.

Authors:  Hye Sun Hyun; Ji Hye Kim; Myung Hyun Cho; Eujin Park; Il-Soo Ha; Hae Il Cheong; Hee Gyung Kang
Journal:  Pediatr Nephrol       Date:  2019-07-04       Impact factor: 3.714

Review 9.  Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.

Authors:  Culley Carson; Kurt G Naber
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients.

Authors:  Sam E Grigg; Patrick Date; Zoe Loh; Ortis Estacio; Douglas F Johnson; Eliza A Hawkes; Andrew Grigg
Journal:  Support Care Cancer       Date:  2018-09-27       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.